文献速递消化系统肿瘤

晚期胰腺癌中FOLFIRINOX保留肿瘤缓解的最佳减量:采用累积相对剂量强度

Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
PubMed 文献 · Eur J Cancer · 2017-03-17

该研究回顾了2012—2015年接受一线FOLFIRINOX治疗的201例胰腺癌患者,最终纳入156例可评估患者,用ROC分析确定累积相对剂量强度(cRDI)对缓解率(RR)和疾病控制率(DCR)的最佳阈值。结果显示,维持RR和DCR的cRDI阈值分别为71.2%和55.3%;未接受预防性G-CSF的患者中cRDI≥80.1%可预测频繁发热性中性粒细胞减少。

要点

  • 维持RR的cRDI阈值为71.2%,维持DCR的cRDI阈值为55.3%。
  • 未接受预防性G-CSF者cRDI≥80.1%可预测频繁FN。
  • 接受预防性G-CSF者cRDI与血液学毒性无相关性。

核心结论

  • 为在晚期胰腺癌中保留最佳RR和DCR,推荐FOLFIRINOX的cRDI分别>70%和>55%。
  • 如cRDI>80%,需要一级G-CSF预防。

研究设计与样本

  • 回顾性分析2012—2015年接受一线FOLFIRINOX治疗的201例胰腺癌患者,最终156例符合条件。
  • 建立改良Hryniuk模型定义累积相对剂量强度(cRDI,%),用ROC分析评估RR和DCR的最佳cRDI阈值。
  • 按是否使用粒细胞集落刺激因子(G-CSF)分析cRDI与中性粒细胞减少及发热性中性粒细胞减少(FN)的关系。

主要发现

  • 156例中133例(48例局部晚期、85例转移性)在首次影像学评估前完成初始治疗计划,中位58天,cRDI为71.8%。
  • ROC曲线显示RR的cRDI阈值为71.2%(敏感度83.3%、特异度64.7%、AUC 0.746),DCR的cRDI阈值为55.3%(敏感度93.6%、特异度62.5%、AUC 0.805)。
  • 96例未接受预防性G-CSF的患者中,cRDI≥80.1%是频繁FN的显著预测因素(敏感度73.7%、特异度72.7%、AUC 0.793)。
  • 接受预防性G-CSF的患者中cRDI与血液学毒性无相关性。

关键数值与推荐

  • RR的最佳cRDI阈值为71.2%,DCR的最佳cRDI阈值为55.3%。
  • 未接受预防性G-CSF者频繁FN的cRDI阈值为80.1%。

临床怎么用

  • 为保留最佳RR和DCR,作者推荐FOLFIRINOX的cRDI分别>70%和>55%。
  • 作者认为如cRDI>80%,需要一级G-CSF预防。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: FOLFIRINOX has increased efficacy but also toxicity. Despite various modified FOLFIRINOX regimens, how much reduction is acceptable remains unclear. This study aimed to find the optimal relative dose intensity (RDI, %) of FOLFIRINOX that preserves tumour responses in patients with advanced pancreatic cancer (PC). METHODS: We reviewed 201 patients with PC treated with first-line FOLFIRINOX during 2012-2015. We established a modified Hryniuk model (http://www.rdicalc.com) and defined cumulative RDI (cRDI, %). The optimal cRDI thresholds for response rate (RR) and disease control rate (DCR) were assessed using receiver operating characteristic (ROC) analysis. Relationships between cRDI and haematologic toxicities (neutropenia and febrile neutropenia [FN]) were also analysed according to use of granulocyte colony-stimulating factor (G-CSF). RESULTS: Among 156 eligible patients, 133 (48 locally advanced PC and 85 metastatic PC) completed initial treatment plan prior to the first radiological evaluation (median 58 days; 71.8% cRDI). For optimal cRDI thresholds, ROC curves showed a 71.2% cRDI for RR (83.3% sensitivity, 64.7% specificity, and 0.746 area under the curve [AUC]) and a 55.3% cRDI for DCR (93.6% sensitivity, 62.5% specificity and 0.805 AUC). Among 96 patients who did not receive prophylactic G-CSF, cRDI ≥80.1% was a significant predictor for frequent FN (73.7% sensitivity, 72.7% specificity and 0.793 AUC). There was no correlation between cRDI and haematologic toxicities in patients receiving prophylactic G-CSF. CONCLUSION: To preserve optimal RR and DCR in advanced PC, cRDI values for FOLFIRINOX >70% and >55%, respectively, are recommended. If cRDI is >80%, primary G-CSF prophylaxis is needed.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee JC, Kim JW, Ahn S, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Eur J Cancer. 2017. PMID: 28324747. doi:10.1016/j.ejca.2017.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。